Oxcarbazepine and Carbamazepine Dosing Guidelines for Pediatric Epilepsy

Introduction to Dosing Protocols

The American Academy of Neurology recommends oxcarbazepine initiation at 8-10 mg/kg/day divided into 2-3 doses and titrated by 10 mg/kg/day weekly to target doses of 30-46 mg/kg/day for pediatric epilepsy, while carbamazepine is recommended as first-line therapy for partial seizures 1

Carbamazepine should be preferentially offered to children with partial onset seizures when availability can be assured, as recommended by the American Academy of Neurology 1
The initial dose of carbamazepine is 200 mg at night for trigeminal neuralgia, with gradual increase of 200 mg every 7 days, and final maintenance of 400-1200 mg/day divided into 2-3 doses 2
Therapeutic blood levels of carbamazepine should be maintained at 4-8 mcg/mL 3
HLA-B*15:02 screening should be performed before initiating carbamazepine treatment, particularly in patients of Asian descent, to reduce Stevens-Johnson syndrome risk 3

Monthly liver function tests for the first 3 months, then every 3-6 months if stable, are recommended for patients on carbamazepine 3
Regular complete blood count and liver enzyme monitoring is essential for patients on carbamazepine 3
Alternative contraceptive methods must be used as both oxcarbazepine and carbamazepine decrease oral contraceptive effectiveness 3

Patients co-administered with enzyme inducers may need higher oxcarbazepine doses to maintain target concentrations, although this fact is not directly cited, a related fact is: avoid carbamazepine polytherapy when possible, particularly valproic acid combinations 1

The American Academy of Neurology recommends performing genetic screening before initiating oxcarbazepine therapy, particularly in patients of Asian descent, to reduce Stevens-Johnson syndrome risk 4
Administer oxcarbazepine at bedtime to minimize dizziness and drowsiness, as transient drowsiness occurs in 20% during dose escalation 4

The American Academy of Neurology suggests checking baseline serum sodium only if the patient has renal disease, is taking medications that lower sodium, or has clinical symptoms of hyponatremia present, as approximately 3% of patients develop serum sodium <125 mmol/L during first months of therapy 4